Comparative Pharmacology
Head-to-head clinical analysis: SYMTUZA versus VIRAC REX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SYMTUZA versus VIRAC REX.
SYMTUZA vs VIRAC REX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SYMTUZA is a fixed-dose combination of darunavir (a HIV-1 protease inhibitor), cobicistat (a CYP3A inhibitor), emtricitabine (a nucleoside reverse transcriptase inhibitor), and tenofovir alafenamide (a nucleotide reverse transcriptase inhibitor). Darunavir inhibits HIV-1 protease, preventing cleavage of viral polyproteins and resulting in immature, non-infectious virus. Emtricitabine and tenofovir alafenamide inhibit HIV reverse transcriptase by competing with natural substrates and causing DNA chain termination. Cobicistat inhibits CYP3A, boosting darunavir exposure.
VirAcRex is a direct-acting antiviral that inhibits the viral RNA-dependent RNA polymerase (NS5B) by acting as a chain terminator, thereby blocking viral replication.
One tablet (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg) orally once daily with food.
300 mg orally once daily with or without food.
None Documented
None Documented
Darunavir: 15 hours (when boosted with cobicistat). Cobicistat: 3-4 hours. Emtricitabine: 10 hours. Tenofovir alafenamide: 0.5 hours (active metabolite tenofovir diphosphate intracellular half-life >60 hours).
Terminal elimination half-life: 2.5-3.5 hours; clinical context: requires thrice-daily dosing to maintain therapeutic levels.
Darunavir: ~80% feces (mostly metabolites), ~14% urine (unchanged 1.5%). Cobicistat: ~86% feces, ~8% urine. Emtricitabine: ~86% urine (unchanged), ~14% feces. Tenofovir alafenamide: ~31% urine, ~47% feces (as tenofovir).
Renal: 30-40% unchanged; biliary/fecal: 50-60% as metabolites; <10% in feces as parent drug.
Category C
Category C
Antiretroviral
Antiretroviral